Access to AVM0703 for Patients with Solid Tumors and Blood Cancers
Sponsor: AVM Biotechnology Inc
ClinicalTrials ID:NCT05974410
This program allows patients with certain solid tumors and blood cancers to access the drug AVM0703 through a special request by a licensed doctor in the US. As of July 2024, 37 patients with various types of cancer have been treated under this program.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
AVM Biotechnology, Inc. offers a drug called AVM0703 to patients with specific solid tumors and blood cancers through a special access program. This program is available when requested by a licensed doctor in the US. As of July 2024, 37 patients have received this treatment, including those with cancers like glioblastoma, breast cancer, ovarian cancer, and others. Most side effects are mild, such as itching during the infusion and a week of mild insomnia.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.